On January 12, Eli Lilly announced a collaboration with Nvidia to establish an AI innovation laboratory in the San Francisco Bay Area, backed by a joint investment of up to $1 billion over five years. The facility will bring together Eli Lilly’s veteran drug discovery scientists and Nvidia’s AI engineers to develop custom machine-learning models designed to accelerate each phase of compound screening and preclinical validation. This initiative follows last year’s deployment of the industry’s most powerful dedicated pharmaceutical supercomputer and the rollout of TuneLab, an AI platform made freely available to smaller biotech firms, positioning Eli Lilly to leverage an ever-growing dataset of trial outcomes for model refinement.

Eli Lilly is in advanced discussions to acquire Ventyx Biosciences, a private biotech with a late-stage glucagon receptor modulator showing promising weight-management efficacy in phase II trials. Analysts estimate the deal price to be in the mid-nine-figures range, which would grant Eli Lilly rights to a candidate that demonstrated average body-weight reductions of 12% over 16 weeks with a favorable safety profile. While the transaction is unlikely to move the stock much in the current quarter, it would bolster the company’s leadership in obesity therapeutics beyond its blockbuster dual-agonist program.

Regulators have informed Eli Lilly that the review of its oral peptide candidate orforglipron will not conclude until April, extending the target action date by three months. This postponement follows additional requests for chemistry, manufacturing and controls data and a comparative safety analysis. Investors reacted with a near 4% one-day share decline, reflecting concerns over an extended approval timeline, though management reaffirmed its production readiness and projected commercial launch in the second half of the year.

Despite recent regulatory setbacks and a premium valuation multiple, Eli Lilly’s fundamentals remain robust. In the latest quarter, the company reported a 54% year-over-year revenue gain driven by its weight-management franchise, with earnings per share up nearly fivefold compared to the prior year. Additional middle- and late-stage assets in diabetes and obesity, along with diversification into oncology and immunology, underpin consensus forecasts for mid-teens annual profit growth through 2028. Coupled with a dividend that has more than doubled over the past five years, many investors view recent share weakness as a buying opportunity for long-term total returns.